Caribou Biosciences
Caribou Biosciences
CRBU
NASDAQ
1.03
USD
-2.83%
About
Caribou Biosciences, Inc. is a clinical-stage clustered regularly interspaced short palindromic repeats (CRISPR) genome-editing biopharmaceutical company. It is engaged in developing transformative therapies for patients with devastating diseases. Its genome-editing platform, including its Cas12a chRDNA technology, enables precision to develop cell therapies that are armored to potentially improve antitumor activity.
Its pipeline includes three clinical-stage allogeneic cell therapies from its chimeric antigen receptor (CAR)-T (CAR-T) cell platform targeting the treatment of hematologic malignancies. CB-010 is the lead product candidate from its allogeneic CAR-T cell therapy platform and is being evaluated in patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL).
Its second product candidate, CB-011, is being evaluated in patients with relapsed or refractory multiple myeloma (r/r MM) in the CaMMouflage phase I trial. CB-012 is its third product candidate..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 690.7K |
| Three Month Average Volume | 44.2M |
| High Low | |
| Fifty-Two Week High | 8.33 USD |
| Fifty-Two Week Low | 1.5 USD |
| Fifty-Two Week High Date | 28 Feb 2024 |
| Fifty-Two Week Low Date | 09 Jul 2024 |
| Price and Volume | |
| Current Price | 2.16 USD |
| Beta | -100,000 |
| Relative Price Change | |
| Four Week Relative Price Change | -4.01% |
| Thirteen Week Relative Price Change | -29.92% |
| Twenty-Six Week Relative Price Change | -74.78% |
| Fifty-Two Week Relative Price Change | -70.73% |
| Year-to-Date Relative Price Change | -68.17% |
| Price Change | |
| One Day Price Change | 2.37% |
| Thirteen Week Price Change | -25.00% |
| Twenty-Six Week Price Change | -72.27% |
| Five Day Price Change | -2.26% |
| Fifty-Two Week Price Change | -63.33% |
| Year-to-Date Price Change | -62.30% |
| Month-to-Date Price Change | -6.90% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 4.16513 USD |
| Book Value Per Share (Most Recent Quarter) | 3.43575 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 4.16513 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 3.43575 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -1.56386 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.46712 USD |
| Revenue Per Share (Trailing Twelve Months) | 0.37626 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -1.38292 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -1.38785 USD |
| Normalized (Last Fiscal Year) | -1.38292 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -1.38292 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -1.38785 USD |
| Including Extraordinary Items (Last Fiscal Year) | -1.38292 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -1.38785 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 3.7177 USD |
| Cash Per Share (Most Recent Quarter) | 2.89554 USD |
| Cash Flow Per Share (Last Fiscal Year) | -1.33516 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -1.35774 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -1.48802 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -395 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -372.20% |
| Pretax Margin (Last Fiscal Year) | -295.49% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -336.63% |
| Operating Margin (Trailing Twelve Months) | -427.56% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -296.05% |
| Net Profit Margin (Trailing Twelve Months) | -372.78% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -7.75% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | 132.34% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | 40.76% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 13.18% |
| EPS Change (Trailing Twelve Months) | 23.70% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 1 |
| Price to Tangible Book (Most Recent Quarter) | 1 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -261,649,000 |
| Net Debt (Last Fiscal Year) | -328,827,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 6 |
| Price to Sales (Trailing Twelve Months) | 6 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 1 |
| Price to Book (Most Recent Quarter) | 1 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 12 |
| Current Ratio (Most Recent Quarter) | 9 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -104,904,000 |
| Free Cash Flow (Trailing Twelve Months) | -130,954,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -19,343 |
| Net Interest Coverage (Trailing Twelve Months) | -1,231 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -25.33% |
| Return on Assets (Trailing Twelve Months) | -34.17% |
| Return on Assets (5 Year) | -99,999.99% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -30.50% |
| Return on Equity (Trailing Twelve Months) | -42.57% |
| Return on Equity (5 Year) | -99,999.99% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -27.24% |
| Return on Investment (Trailing Twelve Months) | -37.56% |
| Return on Investment (5 Year) | -99,999.99% |